Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II National, Open-label, Multicenter Study of Bortezomib (Velcade) in Combination With FLAG-IDA (VFLAG- IDA) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML).

NCT00651781 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT00651781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00651781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II National, Open-label, Multicenter Study of Bortezomib (Velcade) in Combination With FLAG-IDA (VFLAG- IDA) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML).
Lead sponsor
PETHEMA Foundation
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2008
Completion date
February 28, 2013
Enrollment
40 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia